Nominal variables are more than just a name
The analysis of nominal variables is very common in clinical trials. If you want to know more about how to analyze these types of variables, continue reading!
José Alberto Catalá Hernansáiz, new CISO of Sermes CRO
We strengthen our information security management with the appointment as CISO (Chief Information Security Officer) of José Alberto Catalá Hernansáiz, whose professional career has been linked to information technologies for 28 years, and to IT security-related positions for the last 5 years
How to register with OMS to be able to work with CTIS?
To be able to carry out a clinical trial in CTIS, it is previously necessary to be registered with OMS. In this article we explain the OMS registration process for sponsors and sites participating in clinical trials
MSD grants Sermes CRO its Diversity Award 2022
MSD rewards Sermes CRO’s diversity in its “Power of Inclusion Awards 2022”, in the disability category. The global pharmaceutical company Merck Sharp & Dohme selects us among all its vendors as the company that best represents the values of diversity and disability care
Survival Analysis Done Wisely
Menú Home Servicios Expertos en CTIS y la regulación europea de ensayos clínicos Full Service CRO Terapias Avanzadas Soluciones de Inteligencia Artificial Soluciones Tecnológicas personalizadas Soporte personal Patient Centric Unit Quiénes somos Blog Talento Contacto Idiomas Nuestro Blog Ponemos en marcha la semana laboral de cuatro días Hoy comienza el proyecto piloto con una parte […]
CTIS, year 2023: a critical moment for clinical trial management in Europe
What changes to expect in January of 2023 regarding the management of clinical trials in Europe? What have we learned in this first year with CTR 536/2014 in force and CTIS in operation? How much time is left until the transition period ends? How much time have the sponsors of clinical trials to adapt to the new situation?
“Advanced Therapies are the medicine of the future”: Mercedes Zurita, researcher and head of the Cell Therapy Unit at Puerta de Hierro Hospital
We interviewed Dr. Mercedes Zurita, researcher at the Puerta de Hierro Hospital and head of the Cell Therapy Unit at this site, the only one in Spain to offer NC1 therapy for patients with spinal cord injury. This novel treatment is the result of a long and successful research in which Sermes CRO has done its bit by contributing during the development of the entire clinical phase and by providing initial funding through the Sermes Foundation for Clinical Research
Dolores Pérez Méndez, appointed as Quality Assurance director at Sermes CRO
Sermes Cro strengthens its Quality Assurance activities thanks to the appointment of Dolores Pérez Méndez as its new director. She has developed her career within clinical research, specifically in the area of Advanced Therapies, for 10 years
Survival Analysis Done Wisely
Survival analysis is one of the most useful and frequently implemented statistic tools in clinical trial analysis, especially in the oncology field. Although the name of this technique may seem to be linked to the analysis of patients’ survival, it is a very versatile technique! Keep reading if you want to learn more about the features and components of this analysis!
Are we making the most of the new European clinical trials platform, CTIS?
We analyze the usage data of the CTIS in its first three months of operation and we present you the new report that the EMA will publish periodically with the main KPIs. It comprehensively monitors the European clinical trial ecosystem.